<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258072</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10-054</org_study_id>
    <nct_id>NCT04258072</nct_id>
  </id_info>
  <brief_title>Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.</brief_title>
  <official_title>Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI／FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine／Nab-Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine recommended phase 2 dose and to evaluate the safety of vactosertib in&#xD;
      combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma&#xD;
      (PDAC) who have failed first-line gemcitabine and nab-paclitaxel&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Number of patients : Total 24 patients (6-12 patients in phase 1 part and 12 patients in&#xD;
           expansion cohort )&#xD;
&#xD;
        -  Treatment :&#xD;
&#xD;
             -  Vactosertib* 100-300 mg bid for 5 days&#xD;
&#xD;
             -  Liposomal Irinotecan (Onivyde) 70mg/m2 on D1&#xD;
&#xD;
             -  LV 200mg/m2 IV bolus on D1&#xD;
&#xD;
             -  5-FU 2400mg/m2 CIV over 46 hours on D1&#xD;
&#xD;
                  -  Vactosertib will be kindly provided by MedPacto.&#xD;
&#xD;
        -  Disease evaluation: Tumor assessment will be conducted at screening and before Day 1 of&#xD;
           every third cycle starting with Cycle 4&#xD;
&#xD;
        -  Period : Approximately 24 months from the date of Institutional Review Board (IRB)&#xD;
           approval&#xD;
&#xD;
        -  Primary endpoint : To determine recommended phase 2 dose and to evaluate the safety of&#xD;
           vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal&#xD;
           adenocarcinoma (PDAC) who have failed first-line gemcitabine and nab-paclitaxel&#xD;
&#xD;
        -  Secondary endpoint :&#xD;
&#xD;
             -  Progression-Free Survival (PFS) (RECIST 1.1 criteria)&#xD;
&#xD;
             -  Overall Survival (OS)&#xD;
&#xD;
             -  Objective Response Rate (ORR) (RECIST 1.1 criteria)&#xD;
&#xD;
             -  Disease Control Rate (DCR) (RECIST 1.1 criteria)&#xD;
&#xD;
        -  Exploratory endpoint&#xD;
&#xD;
             -  Pharmacokinetic assessment: before treatment, post treatment 1.5h, 4.5h, and&#xD;
                8hPharmacodynamic assessment: to evaluate changes in the amount of p-SMAD in PBMC.&#xD;
&#xD;
             -  Biomarker analysis in pre-treated and post-treated tumor samples&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Vactosertib* 100-300 mg bid for 5 days&#xD;
Liposomal Irinotecan (Onivyde) 70mg/m2 on D1&#xD;
LV 200mg/m2 IV bolus on D1&#xD;
5-FU 2400mg/m2 CIV over 46 hours on D1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>open label,single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vactosertib</intervention_name>
    <description>Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight</description>
    <arm_group_label>open label,single arm</arm_group_label>
    <other_name>TEW-7197</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are males or females ≥ 19 years of age&#xD;
&#xD;
          2. Subjects who have the following history of first-line gemcitabine-based chemotherapy&#xD;
             among patients with cytologically or histologically proven metastatic pancreatic&#xD;
             ductal adenocarcinoma&#xD;
&#xD;
          3. Subjects who can give written informed consent for participation in this trial after&#xD;
             receiving explanations of this trial&#xD;
&#xD;
          4. Subjects who have the following laboratory test values:&#xD;
&#xD;
               -  bilirubin ≤ 1.5 x ULN (upper limit of normal)&#xD;
&#xD;
               -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN&#xD;
&#xD;
               -  serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 40 mL/min&#xD;
                  (Cockcroft-Gault)&#xD;
&#xD;
               -  partial thromboplastin time (aPTT) ≤ 1.5 x ULN&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥ 1,500 cells/µL&#xD;
&#xD;
               -  platelet count ≥ 100,000/µL&#xD;
&#xD;
               -  hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          5. Subjects who have at least a 12-week life expectancy at the Investigator's discretion&#xD;
&#xD;
          6. Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who were treated with surgery, radiotherapy, chemotherapy or investigational&#xD;
             therapy within 2 weeks (note: placement of biliary stent is allowed)&#xD;
&#xD;
          2. Subjects who have uncontrolled CNS metastases (patients who require steroids should be&#xD;
             on a stable or decreasing dose for at least 2 weeks)&#xD;
&#xD;
          3. Subjects who have any contraindications for 5-FU, leucovorin, or nal-IRI&#xD;
&#xD;
          4. Subjects who have moderate or severe cardiovascular disease&#xD;
&#xD;
               -  Subjects who have myocardial infarction, unstable angina pectoris, New York Heart&#xD;
                  Association (NYHA) Class III/IV congestive heart failure, or uncontrolled&#xD;
                  hypertension within 6 months before screening&#xD;
&#xD;
               -  Subjects who have major abnormalities at the Investigator's discretion based on&#xD;
                  electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days&#xD;
                  before screening&#xD;
&#xD;
               -  Subjects who have increase in brain natriuretic peptide (BNP) or increase in&#xD;
                  troponin (over 99th percentile upper reference limit) at Screening (based on the&#xD;
                  normal range of relevant study center)&#xD;
&#xD;
               -  Subjects who have risk factors for ascending aortic aneurysm such as genetic&#xD;
                  disorder and trauma and risk factors for aortic stenosis&#xD;
&#xD;
               -  Subjects who have a history of heart or aorta surgery&#xD;
&#xD;
          5. Subjects who have clinically significant gastrointestinal bleeding within 4 weeks&#xD;
             before screening&#xD;
&#xD;
          6. Subjects who have a known history or suspected hypersensitivity to any excipients of&#xD;
             the investigational product or combination drug(s)&#xD;
&#xD;
          7. Subjects who have received prior treatment targeting the signaling pathway of TGF-β&#xD;
&#xD;
          8. Subjects who have a disease or condition that affects the mechanism of the&#xD;
             investigational product, or are currently using or planning to use:&#xD;
&#xD;
               -  Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme&#xD;
                  (CYP) including CYP1A2, CYP2B6, or CYP3A4&#xD;
&#xD;
               -  Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase&#xD;
                  (UGT) 1A1 (UGT1A1)&#xD;
&#xD;
               -  Drugs that are substrates for the drug transporter multidrug resistance protein 1&#xD;
                  (MDR1) have a narrow therapeutic window or are strong inhibitors of drug&#xD;
                  transporter MDR1&#xD;
&#xD;
               -  Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4&#xD;
&#xD;
          9. Subjects who are unable to swallow tablets&#xD;
&#xD;
         10. Subjects who have a history of or are suspected of drug abuse&#xD;
&#xD;
         11. Female subjects of child-bearing potential who have a positive result on a pregnancy&#xD;
             test at screening or are unable to agree to use an effective barrier method of birth&#xD;
             control to avoid pregnancy during the study period (e.g., sterilization, intrauterine&#xD;
             contraceptive device, combination of oral contraception and barrier contraception,&#xD;
             combination of other hormone delivery systems and barrier contraception, contraceptive&#xD;
             cream, combination of cream, jelly, or form and diaphragm or condom)&#xD;
&#xD;
         12. Subjects, in the opinion of the Investigator, who are unsuitable to participate in the&#xD;
             study&#xD;
&#xD;
         13. Subjects who were treated with other investigational products within 28 days before&#xD;
             screening or within a period shorter than 5-timesthe half-life of the investigational&#xD;
             product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>M.D., PhD,Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

